A retrospective cohort study of 1.1 million obese adults (TriNetX database, 2013–2023) used propensity score matching to compare cancer incidence over 5 years in users versus non users of GLP 1 receptor agonists GLP 1RA use was associated with significantly lower risk of several malignancies: gastrointestinal (HR 0.67), skin (HR 0.62), breast (HR 0.72), female genital (HR 0.61), prostate (HR 0.68), and hematopoietic/lymphoid cancers (HR 0.69) [79]. Here, GLP1R is linked to cancer.